Cookie Settings
Customize Consent Preferences

We use cookies to help you navigate efficiently and perform certain functions. You will find detailed information about all cookies under each consent category below.

The cookies that are categorized as "Necessary" are stored on your browser as they are essential for enabling the basic functionalities of the site. ... 

Always Active

Necessary cookies are required to enable the basic features of this site, such as providing secure log-in or adjusting your consent preferences. These cookies do not store any personally identifiable data.

No cookies to display.

Functional cookies help perform certain functionalities like sharing the content of the website on social media platforms, collecting feedback, and other third-party features.

No cookies to display.

Analytical cookies are used to understand how visitors interact with the website. These cookies help provide information on metrics such as the number of visitors, bounce rate, traffic source, etc.

No cookies to display.

Performance cookies are used to understand and analyze the key performance indexes of the website which helps in delivering a better user experience for the visitors.

No cookies to display.

Advertisement cookies are used to provide visitors with customized advertisements based on the pages you visited previously and to analyze the effectiveness of the ad campaigns.

No cookies to display.

Other cookies are those that are being identified and have not been classified into any category as yet.

No cookies to display.

About Us

The Medicines Patent Pool (MPP) is a United Nations-backed public health organisation working to increase access to, and facilitate the development of, life-saving medicines for low- and middle-income countries. Through its innovative business model, MPP partners with civil society, governments, international organisations, industry, patient groups, and other stakeholders, to prioritise and license needed medicines and pool intellectual property to encourage generic manufacture and the development of new formulations.

To date, MPP has signed agreements with 18 patent holders for 14 HIV antiretrovirals, one HIV technology platform, three hepatitis C direct-acting antivirals, a tuberculosis treatment, a cancer treatment, four long-acting technologies, three oral antiviral treatments for COVID-19 and 12 COVID-19 technologies.

MPP was founded by Unitaid, which continues to be MPP’s main funder. MPP’s work on access to essential medicines is also funded by the Swiss Agency for Development and Cooperation (SDC). MPP’s activities in COVID-19 are undertaken with the financial support of the Japanese Government, the French Ministry for Europe and Foreign Affairs, the German Agency for International Cooperation, and SDC.

Featured

Our Strategy
2023-2025

LAPaL

MPP in Numbers

0

patent holders with MPP signed agreements

0

generic manufacturers and product developers have sublicences from MPP

0 Bn
doses of treatment supplied (Jan 2012 - Dec 2022)
US$0 Bn
dollars saved through MPP'S licences (Jan 2012 - Dec 2022)
By the end of 2030
US$0 Bn
projected dollars saved
0
countries have benefited from access to MPP-licensed products
0 Mn
patient-years of treatment through MPPs generic partners (Jan 2012 - Dec 2022)
0
deaths averted (Jan 2012 - Dec 2022)
By the end of 2030
0
deaths averted

For Everyone Everywhere

Discover where we helped and what we have achieved

 

Patent and licensing status: last updated on 11 May 2021. Disclaimer | Product availability data from MPP sublicensees: last updated in March 2023 (data as of 31 December 2022) | Note: Sales may occur in countries in the absence of registration via procurement channels, registration waivers and/or exemptions

Interactive Map: Click here to view full size

Impact Stories

Key Publications

Contact Us

MPP Logo

Subscribe to our Newsletter

Founded & funded by

Unitaid Logo

Other funders